Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14594217 | 0.87 | CYP2A6 (0.33) | CYP2A6ALDH1A1TDP1 | |
| SCHEMBL697399 | 0.87 | — | — | |
| SCHEMBL60921 | 0.87 | — | — | |
| SCHEMBL10580165 | 0.87 | — | — | |
| SCHEMBL10580174 | 0.87 | — | — | |
| SCHEMBL13902909 | 0.87 | — | — | |
| SCHEMBL12556359 | 0.84 | — | — | |
| SCHEMBL27095711 | 0.84 | — | — | |
| SCHEMBL8709117 | 0.82 | — | — | |
| SCHEMBL17881257 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399878-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-07-15 | — | — | US | claimed |
| US-20070197499-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-08-23 | — | — | US | claimed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | claimed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| CN-1433396-A | Pharmaceutical compounds | NICOX SA (FR) | 2003-07-30 | — | — | CN | claimed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| EP-3142160-A1 | SEMICONDUCTOR ELEMENT AND INSULATING LAYER-FORMING COMPOSITION | Fujifilm Corporation (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-7759392-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2010-07-20 | — | — | US | disclosed |
| CN-100528834-C | Pharmaceutical compounds | NICOX SA (FR) | 2009-08-19 | — | — | CN | disclosed |
| US-20090170941-A1 | Pharmaceutical Compounds | NICOX S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-7399878-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-07-15 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1347744-A1 | SOLID DISPERSIONS OF NITRATE ACTIVE PRINCIPLES | Nicox S.A. (FR) | 2003-10-01 | — | — | EP | disclosed |
| CN-1433396-A | Pharmaceutical compounds | NICOX SA (FR) | 2003-07-30 | — | — | CN | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002051385-A1 | SOLID DISPERSIONS OF NITRATE ACTIVE PRINCIPLES | NICOX S.A. (FR) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197499-A1 | Pharmaceutical compounds | NR0B2, NR0B1, CYP11B2 | CYP2A6 96/4885ALDH1A1 2188/4885TDP1 4059/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | CYP2A6 24/4885ALDH1A1 101/4885TDP1 3288/4885 |
| US-20090170941-A1 | Pharmaceutical Compounds | NR0B2, NR0B1, CYP11B2 | CYP2A6 96/4885ALDH1A1 2086/4885TDP1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.